Tokyo, Japan – 3 April, 2023 – JSR Corporation (Headquarters: Minato-ku, Tokyo, CEO: Eric Johnson) is pleased to announce that it has entered into a joint development agreement and an equity investment agreement with Bacchus Bio innovation Co., Ltd. (Headquarters: Kobe City, Hyogo Prefecture, President and CEO: Mikio Tanji, hereinafter “Bacchus Bio innovation”), Japan's first integrated bio-foundry, for the production of raw materials for products using biomass.
Bacchus Bio innovation is a biotech venture company from Kobe University that aims to create new industries in the "digital x bio" era. It focuses on the basic, elemental technologies and know-how that enable the production of useful substances by such means as microorganisms and metabolic analysis, which are the results of advanced research and development integrating computational science and synthetic biology.
Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
JSR Group is committed to contributing to the preservation of the global environment by providing products and services that are effective in this regard. As a result of this activity, we expect to reduce our environmental impact by drastically reducing the amount of organic solvents used in manufacturing.
Going forward, JSR will continue to strive to realize innovations that lead to new products and services required not only by customers but also by various stakeholders.
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Copy link
https://news.jsrlifesciences.com/224604-jsr-begins-development-of-raw-materials-from-biomassRelated topics
Related news
JSR Life Sciences to Launch Amsphere™ A+, a Next-Generation Protein A Resin for Antibody Drug Purification
Amsphere™ A+ enhances antibody drug production with advanced polymer technology and high binding capacity, debuting at BPI 2024 and BioJapan.
JSR Active Innovation Fund LLC invests in Aillis, Inc., which develops and sells AI medical devices
JSR-AIF participated in the Series D financing of Aillis for the purpose of raising funds to accelerate research and development of AI medical devices, sales, and marketing promotion
Ajinomoto Co., Inc. and JSR Corporation Agree to Collaborate in Development of Global Biopharmaceutical Culture Media...
Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...
JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Value Creation in the Mi...
JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.